ABSTRACT
In persons with hemophilia life expectancy is now approaching that of the general male population, at least in countries that can afford regular replacement therapy with coagulation factor concentrates. The new challenges for comprehensive treatment centers are thus to provide optimal health care for this aging population of patients, who often present not only with the comorbidities typically associated to hemophilia (arthropathy, chronic pain, bloodborne infections), but also with common agerelated illnesses such as cardiovascular disease and cancer. There are no evidence-based guidelines on the management of these conditions, that often require drugs that interfere with hemostasis, enhance the bleeding tendency and warrant more intensive replacement therapy. At the moment, elderly patients with hemophilia affected by other diseases should be managed like their age peers without hemophilia, provided replacement therapy is tailored to the heightened risk of bleeding associated with the need for invasive procedures and drugs that further compromise the deranged hemostasis. More detailed advice is provided on the schedules of replacement therapy that are needed to tackle cardiovascular diseases such as acute coronary syndromes and nonvalvular atrial fibrillation, because these conditions will become more and more frequent challenges for the comprehensive treatment centers.
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INTRODUCTION
Starting from the early 1970s a previously life-threatening and crippling condition such as hemophilia became a gratifying example of successful secondary prevention of a chronic disease. 1 Owing to the increasing availability of coagulation factor concentrates (CFC), at least in high income countries life expectancy increased in persons with hemophilia (PWH) from less than 30 years to over 60. [2] [3] [4] [5] [6] [7] This favorable trend was temporarily halted in the last two A major problem is still the acquired occurrence of alloantibodies that inhibit the activity of coagulation factors. Inhibitors develop in 20 to 30% of patients with severe hemophilia A, whereas this complication is much rarer in severe hemophilia B 10,11 and in patients with mild hemophilia A, who develop inhibitors predominantly in adulthood or even at an old age. [12] [13] [14] Products that bypass the coagulation defect, such as activated prothrombin complex coagulation factors and recombinant factor VIIa, are
For personal use only. on April 3, 2017 . by guest www.bloodjournal.org From usually effective to control bleeding episodes, and alloantibodies can be eradicated in at least 50-60% of patients with inhibitors by immune tolerance therapy based upon the prolonged administration of large doses of recombinant or plasma-derived CFC. 13, 14 On the whole, in the first decade of the third millennium, safe and effective treatment is available for PWH and life expectancy approaches that of the general population. [5] [6] [7] No rose is without thorns. As a consequence of aging, the number of PWH affected with one or more age-related diseases is increasing and newer clinical concerns are emerging. [15] [16] [17] Owing to the current paucity of data, our recommendations are not evidence-based, but stem from the available literature and the clinical experience gained in two large European hemophilia treatment centers.
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HEMOPHILIA-ASSOCIATED COMORBIDITIES IN THE ELDERLY PERSON WITH

HEMOPHILIA
Arthropathy is the epitome of hemophilia-associated comorbidities.
Joint damage increases with aging in an almost linear fashion, not only in severely affected patients but also in moderate hemophilia.
18,19 A study carried out in a cohort of 39 elderly PWH, ranging in age from 65 to 78 years, established that more than half of them had severe damage in all the 6 joints more frequently affected by bleeding (knees, elbows, ankles). 17 There was also a high rate of joint instability and balance dysfunction, so that a large proportion of elderly PWH (70%) had a high risk of falling, spontaneously or after tripping on obstacles. 17 In turns, falls are likely to cause an increasing number of serious injuries and fractures, also owing to osteoporosis and osteopenia.
20-22
An adverse influence on the course of arthropathy may be also due to a more sedentary lifestyle, overweight and obesity, that are commonly associated with both hemophilia and aging.
23,24
On the whole, there will be an increasing need for emergency and elective orthopedic operations with the aging of PWH. Ankle surgery is likely to match knee surgery in frequency, and there will be more revision operations (with a higher risk of bleeding)
in PWH who had their first joint prosthesis implanted 10-15 years ago. More and more elderly patients with inhibitors will also need joint replacement, that are now possible and safe but at exorbitant costs using bypassing agents. [25] [26] [27] 
AGE-RELATED DISEASES IN ELDERLY PERSONS WITH HEMOPHILIA
Cancer. With the exception of HCC in HCV-infected patients and non-Hodgkin lymphomas in HIV-infected patients, it is unclear whether or not in the elderly PWH the incidence of cancer differs from that in age peers without hemophilia. Experimental data indicate that hemophilic mice form less metastasis from experimental melanomas, perhaps owing to less thrombin formation.
45
It is as yet uncertain whether or not this is also true in humans. 46 Two population studies found a lower incidence of cancer, particularly in patients with severe hemophilia, 4, 7 but the prevalence of tumors other than HCC and non-Hodgkin lymphoma was four-fold higher than in the age-matched general population in a small study of elderly PWH. Table 1 higher than those recommended for major orthopedic surgery (see Table 2 and the experiences gained in our large tertiary care centers. This is not unexpected, because if on one hand PWH may be protected from thrombus formation by their hypocoagulability, on the other hand they are exposed at least as normal males to such risk factors for atherosclerosis as aging, smoking and overweight. 51 Other risk factors such as hypertension, Table 4 shows how replacement therapy is planned in PWH when they develop acute coronary syndromes. Peak factor levels should reach at least 80 U/dL at the time of coronary angiography and percutaneous coronary intervention (PCI) with stenting, maintaining these or higher factor levels for as long as therapeutic dosages of heparin are given. Because most PCI-related bleeding complications occur at the arterial access site, a radial access should be preferred over the femoral access. 55 Moreover, for as long as dual antiplatelet therapy is indicated after PCI and stenting, trough plasma levels of 30 U/dL are pursued. The use of bare metal stents instead of drug-eluting stents is preferable, in order to limit to one month the period of dual antiplatelet therapy with aspirin and P2Y12 inhibitors (such as clopidogrel or prasugrel). The choice of bare metal stents, however, must be balanced against the advantage of less restenosis with drugeluting stents. However the latter warrant up to 12 months of dual antiplatelet therapy, and hence more prolonged continuous prophylaxis, as indicated in Table 4 .
For personal use only. on April 3, 2017. by guest www.bloodjournal.org From For secondary antithrombotic prophylaxis in patients who recovered from an acute coronary syndrome, we recommend low-dose aspirin (100 mg) under protection with low-dose continuous CFC prophylaxis (see Table 4 for recommended dosages). Until now, continuous prophylaxis with bypassing agents was never implemented in patients with inhibitors who developed an atherothrombotic event, because the issue of thrombosis as a potential complication of the continuous prophylactic use of bypassing agents remains a concern. healing is enough advanced, should be preferred over bolus infusion.
56,57
Despite the use of these strategies of replacement therapy, the forementioned revascularization procedures and the associated antithrombotic regimens sometime cause excessive bleeding, which may be difficult to control and increase mortality. The hemostatic warrants much lower trough levels of coagulation factors (5 U/dL) to avoid significant bleeding in PWH (Fig. 1) . A huge problem is how to handle antithrombotic prophylaxis in patients with FVIII Other morbidities in the elderly persons with hemophilia. HIV-infected patients. Hence we chose more often hemodialysis, using both heparin and a single dose of CFC replacement aiming at factor levels of 80 U/dL, before and after each procedure.
According to the results of a small cohort study 17 , cognitive impairment is no more frequent in PWH than in their age peers, but it must be pointed out that 78 years was the oldest age. 17 In cases with severe depression, serotonin reuptake inhibitors (SSRI) are frequently used. However, interference of these drugs with primary haemostasis was reported 66 , and their use might increase the risk of upper gastro-intestinal bleeding. 67 To bypass these uncertainties, we usually use drugs other than SSRI to treat depression.
An important aspect of aging is erectile dysfunction, due not only to the normal aging process with the related biosocial problems, but also to such comorbidity as painful arthropathy affecting sexual desire, and to conditions that affect erectile function
For personal use only. on April 3, 2017. by guest www.bloodjournal.org From such as arteriosclerosis and hypertension. 68 The use of multiple drugs to treat the latter may also compromise sexual function. On the whole, living with hemophilia often strains the relationship with the sexual partner, and approximately half of the PWH complained about their limitations during sexual intercourses, specially when they had painful joints and contractures in hips and knees. 68 The oral phosphodiesterase-5 inhibitors (sildenafil and tadalafil) slightly inhibit platelet aggregation in vitro. 69 ,70
Yet they are being used satisfactorily by some of our elderly PWH without an apparent increase in the incidence of bleeding, despite no prophylactic CFC therapy. As seen in normal persons, a few PWH develop previously unnoticed epistaxis during the intake of these drugs, that cause some degree of nasal congestion. Cataract surgery needs replacement therapy with CFC. However, we
give only a single injection one hour before cataract extraction, more with the goal to cover the risk of bleeding associated with
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CONCLUSIONS
Owing to a life-expectancy approaching that of the general population, PWH develop more and more age-related clinical conditions never experienced before, so that treatment centers must enlist the expertise of specialists rarely needed before, like cardiologists and oncologists. Integrated expertise can usually be offered only by large centers specialized in the comprehensive management of PWH, because they can provide at the same time proficiency in coagulation laboratory, hemophilia care and other surgical and medical subspecialties that are unlikely to be available to the general hematologist.
In general, our recommended approach is to treat the diseases occurring in the elderly PWH as they would be treated in age peers without a bleeding disorder. hemophilia. It cannot be ruled out that this second peak in the elderly PWH might produce an increase in inhibitor incidence, particularly in patients with mild disease.
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